Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FLAME - First Line olAparib Maintenance bEyond BRCA An Observational Cohort Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy Beyond BRCA Mutant Status in Newly Diagnosed Advanced Ovarian Cancer

NCT05775549 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05775549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05775549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FLAME - First Line olAparib Maintenance bEyond BRCA An Observational Cohort Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy Beyond BRCA Mutant Status in Newly Diagnosed Advanced Ovarian Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
July 10, 2023
Completion date
October 27, 2023
Enrollment
24 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced ovarian cancer